Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04456491 |
| Other study ID # |
ASCONO |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
September 1, 2021 |
| Est. completion date |
June 30, 2025 |
Study information
| Verified date |
July 2023 |
| Source |
Ryazan State Medical University |
| Contact |
Anton Shakhanov, MD, Cand.Sci. (Med.) |
| Phone |
+7 910 635-95-75 |
| Email |
shakhanovav[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
It is planned to conduct a study of nitric oxide metabolites (nitrates and nitrites),
L-arginine, arginase-1, and asymmetric dimethylarginine in patients with bronchial asthma and
chronic obstructive pulmonary disease, followed by observation to assess the prognosis of the
disease.
Description:
Chronic obstructive pulmonary disease and bronchial asthma have a leading position among
respiratory diseases. A significant contribution to the clinical picture and long-term
prognosis is made by exacerbations of COPD, which makes it relevant to search for methods for
their prediction and prevention. According to the global initiative on bronchial asthma
(GINA), bronchial asthma is characterized by high heterogeneity and the existence of many
phenotypes and endotypes, which makes it relevant to use personalized medicine methods in
patient management and, in particularly, the search for new biomarkers of asthma. Currently,
in clinical practice, some biomarkers of obstructive lung diseases are widely used. Among
them there are the level of eosinophils in the blood and sputum, the level of immunoglobulin
E and the exhaled fraction of nitric oxide (FeNO). Obstructive lung diseases are
characterized by persistent inflammation in the airways, which is accompanied by the
manifestation of elements of systemic inflammation and endothelial dysfunction, which is
associated with an altered release of vasoactive mediators, one of them is nitric oxide (NO).
NO is a powerful vasodilator that is synthesized from L-arginine using the enzyme NO synthase
(NOS). The NO molecule has small lifetime from 3 to 30 s, that's why the search for
biomarkers with a more stable lifetime is relevant. Some of them it's nitric oxide
metabolites, such as nitrates (NO3-), nitrites (NO2-), S-nitrosothiols, 3-nitrotyrosine.
Nitrates and nitrites, which are metabolites of nitric oxide, may be of interest as one of
the promising biochemical markers reflecting NO metabolism in the human body. Earlier in our
study, the relationship between the plasma level of nitric oxide metabolites and the severity
of bronchial asthma was shown, which may be a prerequisite for further study of the
components of the nitric oxide system as potential biomarkers of bronchial obstructive
diseases.
A promising direction in the search for biomarkers related to the nitric oxide system is the
study of L-arginine, which acts as a substrate in the reaction of NO formation. The
bioavailability of L-arginine for NO synthases determines the activity of formation of nitric
oxide in the respiratory tract, as evidenced by the effect of inhaled L-arginine on the level
of exhaled fraction of nitric oxide. Earlier, in a US study, 26 patients with bronchial
asthma showed a significant decrease in plasma L-arginine levels compared with healthy
volunteers, and laboratory animal models showed that a decrease in L-arginine levels leads to
airway hyperreactivity. Currently, a number of pilot clinical interventional studies have
been carried out in which the administration of L-arginine improved the manifestations of
bronchial asthma in some patients, but did not change the frequency of exacerbations in the
total sample of patients. This indicates the possible existence of an endotype of bronchial
asthma associated with impaired functioning of the nitric oxide system, and makes it
promising to study the level of L-arginine in the blood as a potential biomarker of
obstructive lung diseases.
In addition to studying nitric oxide metabolites, substances that affect the formation of NO
should be considered as potential biomarkers of the disease. One such substance is arginase,
under the influence of which L-arginine is converted into L-ornithine and urea. In humans,
two isoenzymes of arginase, arginase 1 and arginase 2, have been identified, which differ in
cellular location and tissue distribution. Both arginase enzymes are expressed in the airways
and can be found in endothelial and epithelial cells, fibroblasts, macrophages, and smooth
muscle cells of the respiratory tract. Further metabolism of L-ornithine leads to the
formation of polyamines and L-proline, which are involved in cell proliferation and
differentiation, as well as in the production of collagen. Scientists have shown that
increased arginase activity in the airways contributes to airway obstruction and
hyperreactivity by decreasing the availability substrate for NOS. As a result, the production
of NO decreases and superoxides form, which react with NO to form peroxynitrite, thereby
increasing airway contractility and inflammation. In addition, increased airway arginase
activity leads to an increase in L-ornithine production, which potentially contributes to
airway remodeling due to stimulation of cell proliferation and collagen formation.
The metabolism of L-arginine depends not only on arginase, but also on the methyltransferase
enzyme, which methylates L-arginine residues, which undergo proteolysis with the formation of
asymmetric and symmetric dimethylarginine (ADMA and SDMA). These amino acids inhibit NOS
activity, since ADMA is a competitive inhibitor of the enzyme, while SDMA is a competitor to
L-arginine transport. Serum ADMA and SDMA, as well as L-arginine concentrations increase with
COPD and increase further with the development of exacerbation. It is important to note that
the concentration of ADMA in blood serum is probably an independent risk factor for long-term
mortality from all causes in obstructive lung diseases and is associated with increased
airway resistance. In recent years, several studies have been conducted examining the
association of ADMA with obstructive lung diseases. Earlier the association of ADMA with the
development of obstructive lung diseases, airway resistance and indicators of the function of
external respiration in patients with obstructive lung diseases was shown.
Thus, there are prerequisites for studying the components of the nitric oxide system, such as
metabolites of nitric oxide, L-arginine, arginase, and asymmetric dimethylarginine, as a
biomarker of obstructive lung diseases. Based on this, it is planned to study of nitric oxide
metabolites (nitrates and nitrites), L-arginine, arginase-1, and asymmetric dimethylarginine
in patients with bronchial asthma and chronic obstructive pulmonary disease, followed by
observation to assess the prognosis of the disease.
The study is aimed at studying the clinical value of the nitric oxide synthesis modulators
(L-arginine, arginase-1 and asymmetric dimethylarginine) in patients with bronchial asthma
and chronic obstructive pulmonary disease, as well as assessing their effect on the prognosis
and the course of diseases .
The study objectives is
1. To assess the levels of modulators of the synthesis of nitric oxide (L-arginine,
arginase-1 and asymmetric dimethylarginine) in the blood of patients with asthma and
chronic obstructive pulmonary disease and their relationship with the clinical course of
the disease.
2. To evaluate the clinical value of the ratio of the levels of modulators of the synthesis
of nitric oxide (L-arginine, arginase-1 and asymmetric dimethylarginine) and the level
of metabolites of nitric oxide (nitrates and nitrites) in patients with bronchial asthma
and chronic obstructive pulmonary disease.
3. To assess the possibility of using the determination of the levels of modulators of
nitric oxide synthesis to predict the course of obstructive lung diseases and prevent
the development of exacerbations of bronchial asthma and chronic obstructive pulmonary
disease.
4. To assess the possibility of developing personalized treatment regimens for obstructive
lung diseases, based on the assesment of the levels of modulators of the synthesis of
nitric oxide (L-arginine, arginase-1 and asymmetric dimethylarginine) in the blood of
patients with asthma and chronic obstructive pulmonary disease.
It is planned to conduct a prospective case-control study in the three study groups. To all
patients will be performed: general clinical examination; Test of Adherence to Inhalers;
clinical and biochemical analysis of the blood; spirometry; assesment of the level of nitric
oxide metabolites in serum using the photocolorimetric method in Griss reaction; assesment of
the level of L-arginine, arginase-1 and asymmetric dimethylarginine in serum by enzyme
immunoassay using the laboratory kit Immundiagnostik (Germany). At the second phase of the
study, lasting 2 years, the prognostic capabilities of assesment the levels of modulators of
nitric oxide synthesis will be evaluated using a combined endpoint, included increase in
level of basis therapy, exacerbation, hospitalisation and mors associated with Asthma and
COPD.
